16 Results for "

natriuresis

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "natriuresis" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-122560
CAS No.: 755002-90-5
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-122560A
CAS No.: 1052515-91-9
Purity:  98.34%
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
loading...
    loading...
Cat. No.: HY-P2469
CAS No.: 1816939-52-2
Synonyms: BNP-45, mouse
Brain Natriuretic Peptide-45, mouse (BNP-45, mouse) is a 45-amino-acid peptide derived from the mouse BNP prohormone, which exhibits natriuretic, diuretic, and vasoactive effects. Brain Natriuretic Peptide-45, mouse contains all amino acid residues deemed critical for the biological activity of natriuretic peptides. Brain Natriuretic Peptide-45, mouse possesses hypotensive and diuretic activities .
loading...
    loading...
Cat. No.: HY-15195
CAS No.: 290815-26-8
Purity:  98.15%
Synonyms: Ro 67-0565; SPP-301
Target:  

Endothelin Receptor

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
loading...
    loading...
Cat. No.: HY-106616
CAS No.: 55294-15-0
Purity:  99.57%
Synonyms: BAY-g 2821; Edrul
Target:  

Sodium Channel

Research Areas:  

Cardiovascular Disease

Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease .
loading...
    loading...
Cat. No.: HY-108649A
CAS No.: 2567869-47-8
Purity:  98.7%
MRS2768 tetrasodium salt is a potent, selective, and metabolically stable P2Y2 receptor agonist with an EC50 of 1.89 μM for the human P2Y2 receptor. MRS2768 tetrasodium salt activates Gq/PLC/PKC signaling, leading to downstream phosphorylation of Akt, eNOS, and ERK, with effects varying by cell type. MRS2768 tetrasodium salt inhibits ENaC via Gq/PKC/Src/Akt to promote natriuresis and lower blood pressure in the kidney. MRS2768 tetrasodium salt activates eNOS to increase NO secretion in endothelial cells. MRS2768 tetrasodium salt drives proliferation via PI3K/Akt in fibroblasts and cancer cells. MRS2768 tetrasodium salt exerts anti-apoptotic effects through PKC/Src/Akt in cardiomyocytes. MRS2768 tetrasodium salt can be applied to investigate P2Y2-dependent pathological processes, including acute kidney injury, chronic kidney disease and renal fibrosis, DOCA-salt induced hypertension, myocardial infarction, pulmonary arterial hypertension, pancreatic cancer, cardiac fibrosis, dry eye disease, as well as shear stress-mediated vascular remodeling and atherosclerosis .
loading...
    loading...
Cat. No.: HY-139037
CAS No.: 28128-41-8
Purity:  97.19%
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

8-Aminoguanine is a endogenous purine. 8-Aminoguanine inhibits PNPase (purine nucleoside phosphorylase). 8-Aminoguanine induces diuresis/natriuresis/glucosuria .
loading...
    loading...
Cat. No.: HY-124404
CAS No.: 82337-46-0
Purity:  ≥99.0%
12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation .
loading...
    loading...
Cat. No.: HY-106616R
CAS No.: 55294-15-0
Synonyms: BAY-g 2821 (Standard); Edrul (Standard)
Muzolimine (Standard) is the analytical standard of Muzolimine. This product is intended for research and analytical applications. Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease .
loading...
    loading...
Cat. No.: HY-W771063
8-Aminoguanine- 13C2, 15N is the 13C- and 15N-labeled 8-Aminoguanine (HY-139037). 8-Aminoguanine is a endogenous purine. 8-Aminoguanine inhibits PNPase (purine nucleoside phosphorylase). 8-Aminoguanine induces diuresis/natriuresis/glucosuria .
loading...
    loading...
Cat. No.: HY-124687
CAS No.: 1914944-54-9
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC50 of 35 nM. ROMK-IN-32 also inhibits hERG with an IC50 of 22 μM .
loading...
    loading...
Cat. No.: HY-122282
CAS No.: 804561-22-6
Target:  

Angiotensin Receptor

Research Areas:  

Cardiovascular Disease

AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .
loading...
    loading...
Cat. No.: HY-19200
CAS No.: 155895-89-9
RB-105 is an inhibitor of angiotensin-converting enzyme (ACE) (Ki = 4.2 nM) and neutral endopeptidase (NEP) (Ki = 1.7 nM). RB-105 after inhibiting ACE reduces the production of Ang II and increase the level of bradykinin. RB-105 after inhibiting NEP increases the level of natriuretic peptide and further increases the level of bradykinin, thereby generating a powerful synergistic effect. RB-105 has significant antihypertensive and natriuretic effects in both spontaneously hypertensive rats and normal blood pressure rats. RB-105 can be used for research on hypertension .
loading...
    loading...
Cat. No.: HY-15195R
CAS No.: 290815-26-8
Synonyms: Ro 67-0565 (Standard); SPP-301 (Standard)
Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
loading...
    loading...
Cat. No.: HY-182635
CAS No.: 83812-65-1
ICI 147798 is an orally effective β-adrenoceptor antagonist with a pKB of 9.1 (in guinea pig right atrium) and 8.8 (in guinea pig trachea). ICI 147798 acts as a diuretic and intraocular pressure-lowering agent. ICI 147798 blocks β-adrenoceptors, inhibits isoproterenol-induced tachycardia and vasodepressor responses, exhibits slowly dissociating, insurmountable antagonism against β1-adrenoceptors, and shows surmountable competitive antagonism against β2-adrenoceptors. ICI 147798 induces natriuresis and kaliuresis, inhibits sodium transport, and reduces intraocular pressure .
loading...
    loading...
Cat. No.: HY-108649
CAS No.: 1047980-83-5
MRS2768 is a potent, selective, and metabolically stable P2Y2 receptor agonist with an EC50 of 1.89 μM for the human P2Y2 receptor. MRS2768 activates Gq/PLC/PKC signaling, leading to downstream phosphorylation of Akt, eNOS, and ERK, with effects varying by cell type. MRS2768 inhibits ENaC via Gq/PKC/Src/Akt to promote natriuresis and lower blood pressure in the kidney. MRS2768 activates eNOS to increase NO secretion in endothelial cells. MRS2768 drives proliferation via PI3K/Akt in fibroblasts and cancer cells. MRS2768 exerts anti-apoptotic effects through PKC/Src/Akt in cardiomyocytes. MRS2768 can be applied to investigate P2Y2-dependent pathological processes, including acute kidney injury, chronic kidney disease and renal fibrosis, DOCA-salt induced hypertension, myocardial infarction, pulmonary arterial hypertension, pancreatic cancer, cardiac fibrosis, dry eye disease, as well as shear stress-mediated vascular remodeling and atherosclerosis .
loading...
    loading...
  • 1